Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Undergraduate Student Research Awards (USRA)

University of Alberta

$6,000.00

A novel Senolytic Strategy to Improve Radiation Therapy for Cervical Cancer

EF 2025-26

Résumé
"Cervical cancer (CC) is the 4th most common cancer among women worldwide and the fastest-increasing gynecological cancer among Canadian females. Despite 35-50% of locally advanced CC (LACC) patients experiencing recurrence or disease progression within 5 years, the standard of care - (chemo)radiation therapy (RT) - has remained the same for decades. Most cervical cancers fall into two histological types, squamous cell carcinoma (SCC) and adenocarcinoma (AC), with AC responding worse to treatment than SCC for unknown reasons. RT aims to kill cancer cells selectively by physically targeting the radiation dose to the tumour and by exploiting cancer cell specific vulnerabilities in the DNA damage response. Yet some damaged cancer cells in the heterogenous tumours avoid cell death by undergoing radiation-induced cellular senescence. Senescent cancer cells can support tumor metastasis and suppression of the anti-cancer immune response via their Senescence Associated Secretory Phenotype. Senescent cancer cells were also proposed to form dormant cancer cells responsible for cancer relapse. Senolytics are drugs that selectively kill senescent cells. We hypothesize that targeting kinases in the cell cycle checkpoint enforcement is a novel strategy to kill radiation-induced senescent CC cells. We will test this by 1) comparing the senolytic activity of combined Myt1/Wee1 inhibitors in irradiated SCC and AC cells, and 2) studying the mode of senolytic activity by live cell imaging to determine the fate of individual senescent cells. Myt1 and Wee1 inhibitors are in clinical trials and may be useful in a ""double punch"" CC treatment approach, where RT can be followed by senolytic administration to clear remaining senescent CC cells."
Programme
Undergraduate Student Research Awards (USRA)
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530990
Name
Oreoluwa Aina
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A novel Senolytic Strategy to Improve Radiation Therapy for Cervical Cancer
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Alberta
Cihramount2
$6,000
Cihrequipment2
$0
Programname2
Undergraduate Student Research Awards (USRA)
Keyworddelim
Cancer; Carcinoma; Cervical; Immune Response; Senescent Cells; Senolytics; Tumour
Abstract
"Cervical cancer (CC) is the 4th most common cancer among women worldwide and the fastest-increasing gynecological cancer among Canadian females. Despite 35-50% of locally advanced CC (LACC) patients experiencing recurrence or disease progression within 5 years, the standard of care - (chemo)radiation therapy (RT) - has remained the same for decades. Most cervical cancers fall into two histological types, squamous cell carcinoma (SCC) and adenocarcinoma (AC), with AC responding worse to treatment than SCC for unknown reasons. RT aims to kill cancer cells selectively by physically targeting the radiation dose to the tumour and by exploiting cancer cell specific vulnerabilities in the DNA damage response. Yet some damaged cancer cells in the heterogenous tumours avoid cell death by undergoing radiation-induced cellular senescence. Senescent cancer cells can support tumor metastasis and suppression of the anti-cancer immune response via their Senescence Associated Secretory Phenotype. Senescent cancer cells were also proposed to form dormant cancer cells responsible for cancer relapse. Senolytics are drugs that selectively kill senescent cells. We hypothesize that targeting kinases in the cell cycle checkpoint enforcement is a novel strategy to kill radiation-induced senescent CC cells. We will test this by 1) comparing the senolytic activity of combined Myt1/Wee1 inhibitors in irradiated SCC and AC cells, and 2) studying the mode of senolytic activity by live cell imaging to determine the fate of individual senescent cells. Myt1 and Wee1 inhibitors are in clinical trials and may be useful in a ""double punch"" CC treatment approach, where RT can be followed by senolytic administration to clear remaining senescent CC cells."
Competitiondate
202505
Approvedterm2
0 yr 4 mths
Pinamesdelim
Oreoluwa, Aina
Approvedterm
0 an 4 mois
Cihrcontribution2
~ $6,000~ $0~